Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04019704 · ClinicalTrials.gov registry record · Phase 3
A Trial of AXS-05 in Patients With Major Depressive Disorder
A Phase 3 study, sponsored by Axsome Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 327
- Enrollment target
NCT04019704 is a Phase 3 study that has completed, run by Axsome Therapeutics. The registered enrollment target is 327 participants.
The verdict
NCT04019704, a Phase 3 study, has completed, sponsored by Axsome Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 327 participants
- Enrollment target
Study Summary
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).
Interventions
- DRUG Placebo
- DRUG AXS-05
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2019-06-20 |
| Est. Completion | 2019-12-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04019704
The ClinicalTrials.gov registry entry for NCT04019704 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 327 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axsome Therapeutics, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04019704 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04019704 about?
NCT04019704 is a clinical study titled "A Trial of AXS-05 in Patients With Major Depressive Disorder". A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of AXS-05 in patients with major depressive disorder (MDD).
What is the current status of trial NCT04019704?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 327 participants. The study started on 2019-06-20. Estimated completion is 2019-12-05.
What interventions are being tested in trial NCT04019704?
The interventions under investigation include: Placebo (DRUG), AXS-05 (DRUG).
Who is sponsoring clinical trial NCT04019704?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.